BRPI1007313A2 - derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. - Google Patents

derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.

Info

Publication number
BRPI1007313A2
BRPI1007313A2 BRPI1007313A BRPI1007313A BRPI1007313A2 BR PI1007313 A2 BRPI1007313 A2 BR PI1007313A2 BR PI1007313 A BRPI1007313 A BR PI1007313A BR PI1007313 A BRPI1007313 A BR PI1007313A BR PI1007313 A2 BRPI1007313 A2 BR PI1007313A2
Authority
BR
Brazil
Prior art keywords
fgf21 derivatives
albumin ligand
albumin
ligand
fgf21
Prior art date
Application number
BRPI1007313A
Other languages
English (en)
Inventor
Birgit Wieczorek
Birgitte Andersen
Henning Thøgersen
Helle WÖLDIKE
Jishu Wang
Kilian Waldemar Conde Frieboes
Kristian Sass Bak-Jensen
Patrick William Garibay
Peter Kresten Nielsen
Rita Slaaby
Tina Møller Tagmose
Xujia Zhang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI1007313A2 publication Critical patent/BRPI1007313A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BRPI1007313A 2009-01-23 2010-01-22 derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. BRPI1007313A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09151227 2009-01-23
EP09152144 2009-02-05
EP09164904 2009-07-08
PCT/EP2010/050720 WO2010084169A2 (en) 2009-01-23 2010-01-22 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use

Publications (1)

Publication Number Publication Date
BRPI1007313A2 true BRPI1007313A2 (pt) 2016-02-10

Family

ID=42356264

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007313A BRPI1007313A2 (pt) 2009-01-23 2010-01-22 derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.

Country Status (14)

Country Link
US (1) US9480753B2 (pt)
EP (1) EP2389190B1 (pt)
JP (1) JP5599822B2 (pt)
KR (1) KR20110117666A (pt)
CN (1) CN102361647B (pt)
AU (1) AU2010207721B2 (pt)
BR (1) BRPI1007313A2 (pt)
CA (1) CA2748593A1 (pt)
ES (1) ES2692495T3 (pt)
IL (1) IL213848A (pt)
MX (1) MX2011007544A (pt)
RU (1) RU2525393C2 (pt)
TW (1) TWI494127B (pt)
WO (1) WO2010084169A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2011089170A2 (en) 2010-01-22 2011-07-28 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
US9120871B2 (en) 2009-01-23 2015-09-01 Novo Nordisk A/S Process for preparing FGF21 with low degree of O-glycosylation
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
US20110236582A1 (en) * 2010-03-29 2011-09-29 Scheuing David R Polyelectrolyte Complexes
JP5767314B2 (ja) 2010-04-16 2015-08-19 ソーク インスティチュート フォー バイオロジカル スタディーズ Ｆｇｆを用いて代謝障害を処置するための方法
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
CN102465129B (zh) * 2010-08-16 2016-05-25 重庆富进生物医药有限公司 人成纤维细胞生长因子21原核细胞中可溶性表达及制备
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3196214B1 (en) 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
CN104364261B (zh) 2012-06-11 2017-04-05 伊莱利利公司 成纤维细胞生长因子21变体
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
US9925241B2 (en) 2013-10-21 2018-03-27 Salk Institute For Biological Studies Mutated fibroblast growth factor (FGF) 1 and methods of use
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
JP6738316B2 (ja) 2014-07-17 2020-08-12 ノヴォ ノルディスク アクティーゼルスカブ 粘度を低下させるためのｔｒｅｍ−１抗体の部位特異的変異誘発
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
TWI681966B (zh) 2014-12-23 2020-01-11 丹麥商諾佛 儂迪克股份有限公司 Ｆｇｆ２１衍生物及其用途
KR20170049320A (ko) * 2015-10-28 2017-05-10 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP2018535964A (ja) 2015-10-30 2018-12-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
KR20170080526A (ko) * 2015-12-31 2017-07-10 한미약품 주식회사 Fgf21 아날로그, fgf21 결합체, 및 이의 용도
WO2017180988A2 (en) 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
EP3502143A4 (en) 2016-08-19 2020-07-15 Ampsource Biopharma Shanghai Inc. BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3612637A4 (en) 2017-04-21 2021-01-27 Yuhan Corporation DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
SG11202013240RA (en) 2018-07-03 2021-01-28 Bristol Myers Squibb Co Fgf21 formulations
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
CN113728013B (zh) * 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113980147B (zh) * 2021-11-26 2023-07-28 中国药科大学 一种聚多肽与fgf21融合蛋白突变体及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1702067A1 (en) * 2003-12-10 2006-09-20 Eli Lilly And Company Muteins of fibroblast growth factor 21
KR20060109940A (ko) * 2003-12-18 2006-10-23 노보 노르디스크 에이/에스 알부민-유사제에 연결된 신규 ｇｌｐ-1 유사체
EP1735340A2 (en) * 2004-03-17 2006-12-27 Eli Lilly And Company Glycol linked fgf-21 compounds
WO2005113606A2 (en) 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
GB0412181D0 (en) * 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2006028595A2 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080176790A1 (en) * 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
JP2008522617A (ja) 2004-12-14 2008-07-03 イーライ リリー アンド カンパニー 線維芽細胞成長因子２１の突然変異タンパク質
JP2008528487A (ja) 2005-01-21 2008-07-31 イーライ リリー アンド カンパニー 心臓血管疾患を治療する方法
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
EP3260129A1 (en) 2007-08-03 2017-12-27 Eli Lilly and Company An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN100587073C (zh) * 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US9480753B2 (en) 2009-01-23 2016-11-01 Novo Nordisk A/S FGF21 derivatives with albumin binder A-B-C-D-E- and their use
US20120035099A1 (en) 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2

Also Published As

Publication number Publication date
JP5599822B2 (ja) 2014-10-01
TWI494127B (zh) 2015-08-01
CN102361647B (zh) 2018-02-16
WO2010084169A2 (en) 2010-07-29
KR20110117666A (ko) 2011-10-27
EP2389190B1 (en) 2018-09-19
US20100216715A1 (en) 2010-08-26
CN102361647A (zh) 2012-02-22
RU2011134454A (ru) 2013-02-27
US9480753B2 (en) 2016-11-01
MX2011007544A (es) 2011-08-12
JP2012515747A (ja) 2012-07-12
TW201032827A (en) 2010-09-16
AU2010207721A1 (en) 2011-07-28
IL213848A0 (en) 2011-07-31
IL213848A (en) 2015-11-30
CA2748593A1 (en) 2010-07-29
EP2389190A2 (en) 2011-11-30
AU2010207721B2 (en) 2015-03-26
WO2010084169A3 (en) 2011-02-17
ES2692495T3 (es) 2018-12-03
RU2525393C2 (ru) 2014-08-10

Similar Documents

Publication Publication Date Title
BRPI1007313A2 (pt) derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
SMT201500036B (it) Derivati di cromenone con attivita' antitumorale
BRPI1010881A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI1010882A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI1012598A2 (pt) Prendedor cego com característica de anti- rotação integrada, sistemas e métodos
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
BRPI1008661A2 (pt) derivados e remédios de aminopirazina
BRPI0813909A2 (pt) Seringa com mecanismo de inutilização
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
BRPI1010533A2 (pt) tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos
BRPI1009221A2 (pt) proteínas de fusão transcriptase reversa estabilizadas.
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI0819258A2 (pt) alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
BRPI0913885A8 (pt) tiadiazoliloxifenilamidinas e seu uso como fungicidas
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
NL2003100A1 (nl) Track system with adjustable width.
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos
BRPI1011960A2 (pt) combinações herbicidas compreendendo tefuriltriona para uso em culturas de arroz.
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01), A61K 47/60 (2017.01), A61K 4

B350 Update of information on the portal [chapter 15.35 patent gazette]